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Abstract
Angiosarcoma is a rare and highly malignant tumor with potential to recur despite treatment, and
carries a poor prognosis. Previous radiation therapy and lymphedema are some of the known risk
factors. We present a case of cutaneous angiosarcoma which occurred at lumpectomy site in a
patient with a history of breast cancer and radiation to the breast. The tumor kept on recurring
repetitively despite continual treatments, and the patient finally succumbed to the disease roughly
four years after initial diagnosis.
Introduction
The sources for our literature search included the data
base PubMed (Medline) 1966-current, Ovid
MEDLINE(R) 1950 to July Week 2 2008, and Cochrane
Database of Systematic Reviews (EBM Reviews).
Case presentation
This is a case of an unfortunate 85 year old Caucasian
female with a past medical history significant for diabetes,
hypertension, lung cancer status-post right middle lobe
lobectomy in 1998, and left breast invasive cancer status-
post lumpectomy and radiation therapy in 2000, who
developed a cutaneous angiosarcoma at the site of
lumpectomy scar in 2004. She underwent left mastectomy
with subsequent treated with paclitaxel (10/5/04 to 1/10/
05). She remained in remission since then, but with resid-
ual chemotherapy related peripheral neuropathies. Dur-
ing one of the routine out-patient oncology clinic follow-
up visits on 1/23/07, she was found to have erythema of
the medial third of the mastectomy scar along with one
inch dark purplish lesion which was fixed to the underly-
ing structures. Computed axial tomography (CAT) scans
of the chest, abdomen and pelvis did not reveal any evi-
dence of tumor. Owing to the attachment of the lesion to
the chest wall and indurated skin around the lesion, she
was not deemed a suitable candidate for surgical resec-
tion. Consequently, she received albumin-bound paclit-
axel chemotherapy from 2/6/07 to 5/8/07 with a
remarkable visible response. She had a complete resolu-
tion of the visible tumor from her anterior chest wall with
no erythema or palpable masses. Afterwards, in 08/07 she
underwent wide surgical excision of left breast mastec-
tomy scar with skin grafting and flap reconstruction of
chest wall by mobilization of the right breast towards the
left. The pathology report of the specimen revealed recur-
rent high grade multi-focal angiosarcoma with positive
deep margins, but no lymphovascular invasion. Re-stag-
ing diagnostic studies of chest, abdomen and pelvis
remained unchanged with no evidence of tumor masses.
On a follow-up visit in 11/07, not surprisingly, she was
noted to have lesions at the scar site along with right sided
breast nodules highly suspicious of the recurrent disease,
but she refused any surgical interventions. She was started
on chemotherapy with 3 weeks on and 1 week off cycles
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of Gemcitabine for a total of 12 treatments. She tolerated
the therapy well but for residual toxicities such as fatigue
and neutropenia which was controlled with Filgrastim.
She once again showed striking improvement with com-
plete resolution of all visible lesions and no palpable nod-
ules. She continued to be in complete remission for 2
months post chemotherapy. She was feeling reasonable
fine until July 2008 when she presented to the emergency
department with worsening shortness of breath. Chest X-
ray demonstrated a large left sided pleural effusion; she
underwent thoracentesis and the fluid cytology was highly
suspicious for malignant cells. She refused any further
management and opted for comfort care. She finally
passed away peacefully in July 2008 – almost 4 years after
the initial diagnosis of angiosarcoma.
Discussion
Angiosarcoma is an uncommon but aggressive malig-
nancy arising from the vascular endothelial cells. About
1% of all adult cancers are comprised of sarcomas, while
2% of all soft tissue sarcomas are comprised of angiosar-
comas [1-3]. They are notorious for local recurrences, sys-
temic metastases, challenging treatment and an overall
poor prognosis. These are categorized as (1) cutaneous
angiosarcoma (2) angiosarcoma of deep soft tissues (3)
angiosarcoma of bone, and (4) breast angiosarcoma.
Cutaneous angiosarcoma has several variants such as (a)
angiosarcoma of the scalp and face, (b) lymphedema-
associated angiosarcoma, such as after mastectomy (Stew-
art-Treves syndrome), (c) radiation-associated angiosar-
coma, and (d) epithelioid angiosarcoma [4]. Most of the
cutaneous angiosarcomas occur in the head and neck
region.[2] The risk of radiation induced sarcomas have
been estimated to range from 0.03 to 0.8%, with radiadi-
otherapy doses ranging from 3000 to 12,440 cGy and a
latency period of up to 12 years for the development of
sarcoma from initial radiation therapy [5,6]. About 1/3rd
of all metastatic angiosarcomas occur in previously irradi-
ated field [7].
In a study of 82 patients with angiosarcoma [2] the mean
age of diagnosis was 65 years, with a range of 22 to 91
years, and 44% were noted in females, and 11% occurred
in the setting of lymphedema or previous radiation. With
regards to the location, 40% were found in skin, 27% in
deep soft tissue, 10% in bone and 9% in breast. Another
retrospective study [8] determined the median age of 52 at
the time of diagnosis, with majority (65%) occurring in
females. The most common location was found to be
breast (38%), skin (21%) and superficial soft tissues
(13%). Metastasis at the time of diagnosis was found in
27% of the patients.
Cutaneous angiosarcoma initiates as a "bruise-like"
patches on the skin, and later progress to become viola-
ceous with ill-defined nodular appearance. Stewart-Treves
syndrome (angiosarcoma arising in the setting of in
chronic lymphedema) and radiation-associated angiosar-
coma usually start as violaceous infiltrating plaques or
nodules. Because of similar physical findings, these
lesions should be distinguished from hemangiomas or
"simple bruises" [4]. Some of the other symptoms include
pain, swelling, or bleeding. Histologically, these tumors
can have various patterns such as vascular channels, sheets
of cells, cells of undifferentiated morphology or a mixed
picture [1]. Immunohistochemical staining with Factor
VIII and UEA-I (Ulex europaeus agglutinin I) is usually
positive in tumor cells of vascular differentiation, the lat-
ter being reported as more sensitive, but less specific for
angiosarcomas [1].
Treatment consists of wide-margin excision whenever fea-
sible, otherwise palliative chemotherapy or radiotherapy
should be considered. Surgery is used as the first-line treat-
ment in a majority (80%), followed by chemotherapy and
radiotherapy in 38 and 30% of patients respectively [8].
Some of the chemotherapeutic agents used in angiosar-
coma include paclitaxel, and doxorubicin with or without
interferon-α2a or ifosfamide, and gemcitabine. A retro-
spective multicenter study conducted by Schlemmer et al
[9] demonstrated the efficacy of Paclitaxel in angiosar-
coma. 13 out of 32 patients in the study had received dox-
orubicin, 5 in combination with ifosfamide as 1st line and
3 had received ifosfamide as 2nd line chemotherapy prior
to treatment with paclitaxel. Complete remission (CR)
was observed in one, partial response (PR) in 19, with an
overall response rate of 62.5%. In patients with angiosar-
coma of face and scalp, the overall response rate was 75%
(1 CR and 5 PR), while it was 58% (14 PR) in patients
with angiosarcoma of other sites. The progression free sur-
vival was 7.6 months for all patients. A phase II prospec-
tive study [7] of metastatic angiosarcoma patients
evaluated the efficacy of weekly Paclitaxel. 22 of 30
patients had previous surgery and 14 had previous anthra-
cyclin based chemotherapy. 15, 11, 6 and 4 patients
respectively received 3, 4, 5 and 6 cycles of paclitaxel, out
of which 1 patient had grade 4 toxicity (neutropenia), 27
patients had grade 2 and 3 toxicities including myalgias
(15/27), leuco-neutropenia (14/27), infections (6/27),
and anemia (4/27). Of 23 patients available for the final
analysis, 4 (14%) had partial response, 14 (56%) had sta-
ble disease and 7 (30%) had progressive disease, with an
overall tumor-control rate of 70% (stable disease + partial
response). Retrospective studies indicate that although
Paclitaxel is efficacious in the treatment of angiosarcoma,
it may not be superior to non-taxane base chemotherapies
[10]. Individual reports indicate favorable results with
combination therapy using liposomal doxorubicin and
interferon-α2a. A complete response for more than 15
months was maintained in a patient with angiosarcomaPublish with BioMed Central    and   every 
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of forehead and multiple bilateral pulmonary nodules
[11] Gemcitabine has also been determined to efficacious
in isolated reports [12].
Angiosarcomas have a poor prognosis even with treat-
ment. Studies [8] demonstrated a relapse rate of 56% and
death in 47% of patients within a median follow-up
period of 1.8 years. 5-year survival is about 23% and 48%
respectively in patients with and without metastasis at the
time of diagnosis [8]. Bone and liver metastases are con-
sidered to be significant adverse prognostic factors [8].
Median survival ranges from 21 to 40 months depending
upon the study [8,10].
Given the vascular origin of the tumor, it may not be sur-
prising to potentially discover a role of some of the novel
angiogenesis inhibitors in the treatment this tumor. Pro-
spective trials evaluating various treatment options are
limited owing to the rarity of this tumor. Further studies
need to be conducted to truly unravel this enigmatic
entity.
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